Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases.

This study has been withdrawn prior to enrollment.
(Unfortunately we had unforeseen difficulty recruiting to this study. Therefore we have decided to halt the study and not publish the results.)
Information provided by:
Mayo Clinic Identifier:
First received: September 14, 2005
Last updated: November 12, 2009
Last verified: November 2009

Hand and foot skin diseases, such as dermatitis and psoriasis, that do not respond to topical creams can be treated with ultraviolet light therapy. Topical psoralen plus ultraviolet A (PUVA) is commonly used to treat these conditions, but requires additional time for the hands and feet to soak in psoralens before the light treatment. Newer narrowband ultraviolet B (NBUVB) units have become available which allow for light treatment without soaking first. The purpose of this study is to determine if NBUVB is as effective as PUVA for hand and foot skin diseases.

Condition Intervention Phase
Procedure: Psoralens plus ultraviolet A light therapy and narrowband ultraviolet B light therapy
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial of Narrowband Ultraviolet B vs Topical Psoralen Plus Ultraviolet A Photochemotherapy for Hand and Foot Dermatoses

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Number of treatments required to reach clearance

Secondary Outcome Measures:
  • Change in symptom score (erythema, scaling/hyperkeratosis, papular/vesicular eruption, and fissures)
  • Change in global score
  • Number of patients reaching clearance
  • Adverse effects
  • Number of days in remission

Enrollment: 3
Study Start Date: March 2005
Estimated Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Bilateral hand or foot skin disease (dermatitis, psoriasis, etc.) with symmetric distribution and severity.

Exclusion Criteria:

Age <18 years Pregnancy Liver disease Kidney disease History of skin cancer Phototherapy or systemic therapy for the skin condition in the preceding 3 months

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00217009

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Mark D. Davis, M.D. Mayo Clinic
  More Information

No publications provided

Responsible Party: Mark D Davis, M.D, Mayo Clinic Identifier: NCT00217009     History of Changes
Other Study ID Numbers: 2435-04
Study First Received: September 14, 2005
Last Updated: November 12, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Skin Diseases
Dermatologic Agents
Pharmacologic Actions
Photosensitizing Agents
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on November 20, 2014